Clinical trial

SucroMet Nutritional Intervention Trial

Recruiting now · Not applicable · 1 countries · Registry ID NCT07656298

Recruiting nowNot applicableInterventional

What this study is about

SucroMet is designed to evaluate how adding two commonly used sweeteners-sucrose (table sugar) and sucralose (a low-calorie sweetener)-at low and high doses may influence glucose regulation, including insulin resistance and fasting plasma glucose, in adults aged 18 to 65 years with normal weight, overweight, or obesity. The low-dose intervention consists of 5% of the Estimated Energy Requirement (EER) from sucrose or 5 sucralose tablets per day (approximately 33.35 mg/day of sucralose). The high-dose intervention consists of 10% of EER from sucrose or 10 sucralose tablets per day (approximately 66.7 mg/day of sucralose). These doses maintain the planned 1:2 exposure ratio between the low- and high-dose intervention groups. Before the intervention begins, participants' habitual dietary intake is assessed and, when necessary, minor dietary adjustments are made to support a stable overall eating pattern while maintaining energy intake. Participants then complete a four-week run-in period during which these recommendations are followed, and dietary records are used to verify dietary stability before the intervention starts. Participants will consume the assigned sweetener incorporated into foods or beverages that they already consume as part of their habitual diet, without substantial changes to their usual eating patterns. The intervention includes two consecutive 12-week phases, one involving solid food intake and the other involving liquid intake, separated by a two-week washout period. This design allows evaluation of the effects of sweetener type, dose, and mode of consumption. The primary outcomes are changes in glucose regulation, including fasting plasma glucose and insulin resistance assessed by HOMA-IR. Secondary outcomes include changes in body composition, anthropometric measurements, blood pressure, routine biochemical parameters, gut microbiota composition, DNA methylation patterns in peripheral blood cells, and biomarkers related to inflammation, oxidative stress, and metabolomic profiles measured in blood and urine. Participants will attend scheduled study visits for anthropometric assessments, dietary evaluations, and biological sample collection. Blood, urine, and stool samples will be obtained at baseline and after each intervention phase. The study aims to address the following questions: 1. Do metabolic responses to sucrose and sucralose, including changes in insulin resistance (HOMA-IR) and fasting plasma glucose, differ according to participants' body mass index (BMI)? 2. Do low and high doses of sucrose and sucralose differentially affect glucose regulation, body composition, and metabolic health? 3. Does the mode of intake (solid versus liquid) influence changes in gut microbiota composition? 4. Are changes in DNA methylation patterns in peripheral blood cells associated with the consumption of sucrose and sucralose at different doses and in different forms? 5. Do different doses of sucrose and sucralose influence biomarkers related to inflammation, oxidative stress, and metabolomic profiles?

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 65 Years

SexAll

Healthy volunteersAccepted

ConditionOverweight , Obesity, Glucose Metabolism

Full registry criteria

Inclusion Criteria: * Adults aged 18 to 65 years at the time of enrollment. * Body Mass Index (BMI) between 18.5 and 39.9 kg/m². * Men and women who report a preference for sweet taste and habitual consumption of sugar and/or sweeteners. * Individuals in good general health, as determined by: 1. Medical history and clinical evaluation; 2. Absence of uncontrolled chronic diseases, such as diabetes, metabolic syndrome, severe hypertension, or advanced liver or renal disease; and 3. Baseline biochemical parameters within normal reference ranges, including fasting plasma glucose \<100 mg/dL, HbA1c \<5.7%, normal liver and renal function (ALT/AST and creatinine within reference ranges), and blood pressure \<140/90 mmHg without pharmacological treatment. * Less than 4 hours per week of moderate-to-vigorous physical activity. * Not following special or restrictive diets (e.g., ketogenic, strict vegetarian, or vegan diets). * Not taking medications known to affect metabolism, including, for example, antidiabetic drugs, systemic corticosteroids, weight-loss medications, or high-dose antioxidant supplements, except for stable use of hormonal contraceptives. * Willingness to maintain habitual diet and physical activity throughout the study, with the only modification being the assigned sweetener intervention. * Ability and willingness to comply with all study procedures and scheduled visits. * Provision of written informed consent before participation. Exclusion Criteria: * Gastrointestinal disorders influencing digestion or nutrient absorption (e.g., inflammatory bowel disease, celiac disease, malabsorption syndromes). * History of cancer not in remission. * Uncontrolled thyroid disorders. * History of bariatric surgery or extreme weight loss within the past 12 months. * Pregnancy, breastfeeding, or planning pregnancy during the study period. * Acute illness, major infection, hospitalization, or major surgery within the previous 6 months. * Any condition that, in the investigators' judgment, could compromise participant safety, protocol adherence, or interpretation of the study results.

Treatments and study arms

Sucrose- Low dose

Behavioral

Sucrose administered at a dose equivalent to 5% of the participant's estimated daily energy requirement. The required amount is individually calculated and provided in pre-weighed sachets for daily consumption. Participants consume the assigned dose in foods or beverages during both intervention periods according to the crossover schedule.

Sucrose - High Dose

Behavioral

Sucrose administered at a dose equivalent to 10% of the participant's estimated daily energy requirement. The required amount is individually calculated and provided in pre-weighed sachets for daily consumption. Participants consume the assigned dose in foods or beverages during both intervention periods according to the crossover schedule.

Sucralose - Low Dose

Behavioral

Sucralose tablets administered at a total dose of approximately 33.35 mg/day (5 tablets/day). Tablets are consumed daily and distributed across meals. Participants receive the assigned dose throughout both intervention periods and consume the sweetener in both solid and liquid forms according to the study crossover schedule.

Sucralose - High Dose

Behavioral

Sucralose tablets administered at a total dose of approximately 66.7 mg/day (10 tablets/day). Tablets are consumed daily and distributed across meals. Participants receive the assigned dose throughout both intervention periods and consume the sweetener in both solid and liquid forms according to the study crossover schedule.

Primary outcomes

Change in HOMA-IR IndexBaseline (before intervention) and End of each 12-week intervention phase

Insulin resistance will be assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Results will be reported as HOMA-IR values.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Hospital Universitario Virgen de la Victoria🇪🇸 Málaga, Malaga, Spain

Open map

Libia Alejandra García Flores, PhD.Contact

Email · Call 0034636938538

Lourdes Garrido Sánchez, PhD.Contact

Email · Call 0034629910317